Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak

Novo Nordisk was downgraded to Sell by Deutsche Bank, with Emmanuel Papadakis cutting the rating to sell from hold and reducing the price target by 9% to 265 kroner. The downgrade follows a ~70% stock-price decline from its peak, though broader analyst sentiment remained reluctant to fully advise selling prior to this move.

Analysis

The key market mechanism is not the downgrade itself but the signal that the earnings revision cycle may still be rolling over. After a major de-rating, an analyst move to sell often matters less as new information and more as confirmation that forward estimates are still too high; that tends to extend multiple compression for another 1-2 quarters even if the stock has already fallen hard. The deeper issue is whether obesity franchise growth is normalizing faster than the market’s long-duration model assumed.

Relative value looks more attractive than an outright short. The cleanest expression is long LLY versus short NVO: Lilly still has the stronger manufacturing ramp, broader GLP-1/obesity optionality, and more credible path to defend premium valuation if category growth slows but remains large. Second-order benefit also accrues to pharmacies, distributors, and payers if the category enters a price war; that would pressure NVO’s mix and margins while improving access dynamics for competitors with larger scale or better pipeline breadth.

The contrarian view is that a 70% drawdown has already discounted a lot of bad news, and NVO’s balance sheet means this is an equity-duration problem, not a credit stress event. The key falsifier for a bearish stance is an earnings call that stabilizes volume/margin expectations or shows faster-than-feared normalization in supply and market share. If that happens, the stock could mean-revert sharply because positioning is likely already defensive; if not, the next 1-3 months could bring another leg down on guidance cuts or pricing pressure headlines.

Key Decisions for Investors

• Preferred expression: long LLY / short NVO as a 1-3 month relative-value pair; thesis works if obesity growth decelerates but category remains durable. Falsify on NVO guidance stabilization or share gain evidence.
• If needing a directional short, use small-size NVO put spreads into the next earnings/guidance window rather than stock shorting; downside is likely slower and more volatile than the headline suggests.
• Avoid adding to NVO long until there is evidence of margin stabilization or a credible next-wave obesity catalyst; otherwise the stock can continue to de-rate even on in-line results.
• Watch for follow-on analyst downgrades and estimate cuts across GLP-1 names over the next 1-2 months; that would confirm the revision cycle is still negative and extend pressure on NVO.
• Set a review trigger around the next quarterly report: if gross margin or U.S. prescription growth misses again, treat it as confirmation that the move is underdone; if both stabilize, consider covering shorts and rotating into the pair.